Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voriconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voriconazole SCHEMBL29449338 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL28720611 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL824156 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL1554444 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29378592 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29449335 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL371715 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL3949267 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL4709722 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL3713297 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215232-A1 | A COMPOSITION COMPRISING A SAPONIN AND/OR AN ANTHELMINTIC AND/OR A MITOCHONDRIAL UNCOUPLER FOR THE TREATMENT OF LIVER DISEASE | RAINCASTLE BIO. LIMITED (GB) | 2025-10-16 | — | — | WO | claimed |
| CN-119510476-A | Voriconazole structure identification method based on multidimensional nuclear magnetic resonance | 武汉商学院 | 2025-02-25 | — | — | CN | claimed |
| EP-4019509-A1 | METHOD FOR PREPARING VORICONAZOLE L-CAMPHORSULPHONATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2022-06-29 | — | — | EP | claimed |
| EP-4633677-A1 | VIROPORINS BLOCKERS/INHIBITORS AS ANTI-INFLUENZA AGENTS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-10-22 | — | — | EP | disclosed |
| CN-119868580-A | Cyclodextrin inclusion compound and preparation method thereof | 江苏东科康德药业有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119823105-A | Preparation method of racemic voriconazole | 苏州第四制药厂有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119564599-A | Preparation process of voriconazole intermediate liquid medicine for injection | 湖南赛隆药业(长沙)有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119555826-A | Method for detecting 4- (1, 1-dibromoethyl) -6-chloro-5-fluoropyrimidine in voriconazole | 珠海润都制药股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119510476-A | Voriconazole structure identification method based on multidimensional nuclear magnetic resonance | 武汉商学院 | 2025-02-25 | — | — | CN | disclosed |
| CN-119499192-A | Preparation method of voriconazole for injection | 湖南赛隆药业(长沙)有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119306703-A | Synthesis method of voriconazole | 湖北午时医药研究院有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-106432198-B | Method for preparing voriconazole split intermediate | 浙江华海药业股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114965912-A | Voriconazole structure detection method based on spectrum characteristics | 丁力 | 2022-08-30 | — | — | CN | disclosed |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| EP-4019509-A1 | METHOD FOR PREPARING VORICONAZOLE L-CAMPHORSULPHONATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-112898273-B | Synthetic method and application of voriconazole | 海南锦瑞制药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| CN-114344245-A | Voriconazole external preparation and preparation method thereof | 浙江普利药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114191387-A | Preparation method of voriconazole oral liquid | 苏州海景医药科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3511326-B1 | METHOD FOR PREPARING VORICONAZOLE L-CAMPHORSULPHONATE AND VORICONAZOLE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | CYP3A4 4/4885CYP2C9 31/4885CYP2C19 40/4885 |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | CYP3A4 4/4885CYP2C9 31/4885CYP2C19 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.